Authors

Latest:

Dr Secord on the Safety of Mirvetuximab in Recurrent Platinum-Sensitive Ovarian Cancer

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Angeles Alvarez Secord, MD, Duke University Medical Center

Angeles Alvarez Secord, MD, Duke University School of Medicine

Angelica D'Aiello, MD

Latest:

Early-Stage NSCLC Is Ripe for Change

Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.

Angelica Welch

Latest:

Study Addresses Breast Cancer Monitoring Burden on Metastatic Patients

Melissa K. Accordino, MD, MS, discusses ways to improve the monitoring of patients with metastatic breast cancer.

Angelo Fama, MD

Latest:

Dr. Fama on GBV-C Infection and Risk of Lymphoma

Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.

Angus Dalgleish, MD

Latest:

Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

Ani Balmanoukian, MD

Latest:

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

Ani S. Balmanoukian, MD

Latest:

Dr. Balmanoukian on Clinical Trials With Immunotherapy in GU Cancers

Ani S. Balmanoukian, MD, director of Thoracic Oncology, and associate director of the Phase I Immune-Oncology Program at The Angeles Clinic and Research Institute, discusses the importance of clinical trials investigating immunotherapy for patients with genitourinary (GU) cancers.

Anis Hamid, MBBS

Latest:

Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Anita Shaffer

Associate Director of Editorial, Print

Latest:

Neoadjuvant Therapy Helps Shape Changing Landscape of Early-Stage NSCLC

The treatment of patients with early-stage non–small cell lung cancer is rapidly evolving across the spectrum of care, particularly in the neoadjuvant setting, where evidence in favor of systemic chemoimmunotherapy regimens is growing.

Anita T. Shaffer

Associate Director of Editorial, Print

Latest:

New Strategies for Targeting CTLA-4 Emerge

In 2011, the development of ipilimumab, a novel antibody targeting the CTLA-4 immune checkpoint, helped launch the modern era of anticancer immunotherapy.

Anjali Advani, MD

Latest:

ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape

Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.

Ankit Kansagra, MD

Latest:

Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic Cancers

Ankit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.

Ann H. Klopp, MD, PhD

Latest:

Dr. Klopp on the Future of Chemoradiation in Endometrial Cancer

Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.

Ann H. Partridge, MD, MPH

Latest:

Dr Partridge on Unique Treatment Challenges for Young Patients with ER+/Node-Positive Breast Cancer

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

Ann Janssens, MD

Latest:

Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients

A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.

Ann LaCasce, MD

Latest:

Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin Combo

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

Ann-Lii Cheng, MD

Latest:

Dr. Cheng on the Need For Biomarkers in HCC

Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.

Ann-Lii Cheng, MD, PhD

Latest:

Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials

Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.